Surfix Diagnostics, NKI and CRCbioscreen join forces to validate biomarkers for colorectal cancer screening
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Globally, colorectal cancer impacts 1.9 million people each year, standing as a leading cause of cancer mortality
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Subscribe To Our Newsletter & Stay Updated